-8.2 | | Slc1a6 | 'induced extraembryonic endoderm stem cell; grown in ES cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
-7.2 | | Slc1a6 | 'neural stem cell' vs 'niche cell' | cell type | Transcription profiling by high throughput sequencing of three populations of primary dentate gyrus cells |
-6.5 | | Slc1a6 | 'extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
5.1 | | Slc1a6 | 'SMRT shRNA; CpG; 6 hour' vs 'none; none; 0 hour' | RNA interference, stimulus, time | RNA-seq of Control and SMRT KD CD8α+ DCs at 0hr and 6hr CpG stimulation |
-4.8 | | Slc1a6 | 'induced extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
-4 | | Slc1a6 | 'myeloid lineage restricted progenitor cell' vs 'long term hematopoietic stem cell' in 'Elp3fl/fl' | cell type, genotype | RNA-seq of long-term hematopoietic stem cells and myeloid progenitors of control mice or mice conditionally deficient for Trp53 or Elp3 or both genes in the hematopoietic system |
-3.4 | | Slc1a6 | 'neural progenitor cell' vs 'niche cell' | cell type | Transcription profiling by high throughput sequencing of three populations of primary dentate gyrus cells |
-3.3 | | Slc1a6 | 'extraembryonic endoderm stem cell; grown in ES cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
3 | | Slc1a6 | 'Irx3 knockout' vs 'control' at '7 day' | genetic modification, time | RNA-Seq of mouse Irx3-KO and Control ME3 cells on days 1 and 7 of adipogenic differentiation |
2.9 | | Slc1a6 | 'Duchenne muscular dystrophy' vs 'normal' | disease | RNA-seq comparison of immortalised myoblasts from dystrophic and WT mice |
2.9 | | Slc1a6 | 'AZD5069; 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
2.9 | | Slc1a6 | 'AZD7507; AZD5069 (at same dosage); 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
-2.8 | | Slc1a6 | 'interferon gamma' vs 'dexamethasone; 100 nanomolar' | compound, stimulus | RNA-Seq of murine lung endothelial cells stimulated with IFN-gamma and dexamethasone |
2.8 | | Slc1a6 | '15 day' vs '3 day' | time | Transcription profiling time series of mouse embryonic chondrocyte differentiation |
2.8 | | Slc1a6 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
2.6 | | Slc1a6 | 'Id2_Id3_double knockout' vs 'wild type' in 'CD4+TCRb+CD8– cell; thymus' | cell type, genotype, organism part | Transcription profiling by high throughput sequencing of Id-proteins (Id2 and Id3) gene knockout cells |
2.5 | | Slc1a6 | 'neuron' vs 'differentiating progenitor' | cell type | Transcription profiling by high throughput sequencing of proliferating neural stem cells, differentiating neurogenic progenitors and newborn neurons using a dual-reporter mouse line |
2.5 | | Slc1a6 | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-2.5 | | Slc1a6 | 'K-ras mutant/Wt1-null' vs 'wild type' | genotype | Transcription profiling by array of wild type, K-ras mutant, Wt1-null, and double K-ras mutant/Wt1-null mouse embryonic fibroblasts |
2.3 | | Slc1a6 | '12 day' vs '3 day' | time | Transcription profiling time series of mouse embryonic chondrocyte differentiation |
2.3 | | Slc1a6 | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
2.3 | | Slc1a6 | 'Er1F/-' vs 'wild type genotype' | genotype | RNA-Seq profiling of ERCC1-XPF DNA repair defect (Er1F/-) versus wild type (Er1F/+) macrophages |
-2.2 | | Slc1a6 | 'adenoviral vector expressing human ACE2' vs 'empty adenoviral vector' | genotype | RNA-seq of SARS-CoV-2 infected lungs from mice sensitized for SARS-CoV-2 infection by Ad5-hACE2 transduction compared to non-sensitized mice |
2.1 | | Slc1a6 | 'Sall4 homozygous knockout' vs 'wild type genotype' | genotype | RNA-Seq of Sall4 mutants in mouse embryonic stem cells |
2.1 | | Slc1a6 | 'Pkhd1Cre; Pkd2 F/F' vs 'wild type' | genotype | Next Generation Sequencing of PKD2 mutant mice kidneys |
-2.1 | | Slc1a6 | 'K-ras mutant' vs 'wild type' | genotype | Transcription profiling by array of wild type, K-ras mutant, Wt1-null, and double K-ras mutant/Wt1-null mouse embryonic fibroblasts |
-2.1 | | Slc1a6 | 'Trp53 knockout' vs 'wild type genotype' in 'Nutlin-3a; 10 micromolar' | compound, phenotype | Residual tumor suppressor activities of tumorigenic p53 mutants enhance survival under chemotherapy |
-2 | | Slc1a6 | 'induced neural stem cell' vs 'mouse embryonic fibroblast cell' | cell type | Gene expression profile of mouse induced neural stem cells |
-2 | | Slc1a6 | 'Trp53 knockout' vs 'wild type genotype' in 'dimethyl sulfoxide; 0.1 microliter' | compound, phenotype | Residual tumor suppressor activities of tumorigenic p53 mutants enhance survival under chemotherapy |
-1.9 | | Slc1a6 | 'PolgD257A/D257A' vs 'wild type' | genotype | Transcription profiling by array of cochlea from PolgD257A/D257A mice |
1.8 | | Slc1a6 | 'dexamethasone; 100 nanomolar' vs 'none' | compound, stimulus | RNA-Seq of murine lung endothelial cells stimulated with IFN-gamma and dexamethasone |
1.8 | | Slc1a6 | '10 day' vs '0 day' | age | Transcriptional profiling by array of mouse cerebellar cortex during postnatal development |
-1.8 | | Slc1a6 | 'Dcrfx/fx;MisCre' vs 'wild type' in '5 day' | age, genotype | Transcription profiling of testis from wild type mice and mice with a Sertoli-specific ablation of Dicer |
-1.7 | | Slc1a6 | 'oxidized low density lipoprotein; 25 microgram per milliliter' vs 'none' in 'CD36 knockout' | compound, genotype | Quantitative analysis of wild type and cd36-/- murine peritoneal macrophage transcriptomes |
-1.6 | | Slc1a6 | '5,9-endoperoxy-cholest-7-en-3β,6α-diol' vs 'vehicle (cyclodextrin)' | compound, time | Array results for differential gene expression in 661W, a mouse cone photoreceptor-derived cell line, comparing cells incubated with vehicle controls vs. those treated with either of two 7-dehdyrocholesterol-derived oxysterols or cholesterol |
1.6 | | Slc1a6 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'A/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
1.6 | | Slc1a6 | 'Pkhd1Cre; Pkd2 F/F; miR-21null' vs 'wild type' | genotype | Next Generation Sequencing of PKD2 mutant mice kidneys |
-1.5 | | Slc1a6 | 'cholesterol' vs 'vehicle (cyclodextrin)' | compound, time | Array results for differential gene expression in 661W, a mouse cone photoreceptor-derived cell line, comparing cells incubated with vehicle controls vs. those treated with either of two 7-dehdyrocholesterol-derived oxysterols or cholesterol |
1.5 | | Slc1a6 | 'dexamethasone; 100 nanomolar; interferon gamma' vs 'none' | compound, stimulus | RNA-Seq of murine lung endothelial cells stimulated with IFN-gamma and dexamethasone |
-1.5 | | Slc1a6 | 'heat-shocked at 42 degreeC' vs 'grown at 33 degreeC' in 'HdhQ111 knock-in' | genotype, growth condition | Transcription profiling by array of mouse wild type and Htt mutant striatal cells upon heat shock |
-1.5 | | Slc1a6 | 'P19; transduced with NeuroD2 lentivirus' vs 'P19; control' | cell line, treatment | Genetic and epigenetic determinants of neurogenesis and myogenesis [expression profiling] |
1.4 | | Slc1a6 | 'Sall4 -/-' vs 'wild type genotype' | genotype | RNA-Seq of mouse embryonic stem cells in response to changes in Sall4 |
1.4 | | Slc1a6 | 'Chikungunya virus; late stage encephalitis' vs 'mock infection' | infect, time | Transcriptomic profiling of the brains of WNV and CHIKV infection-induced encephalitis in young mice after 2, 3 or 5 days post infection |
1.4 | | Slc1a6 | 'FusΔNLS/+' vs 'wild type genotype' at '12 hour' | genotype, time | Mutant FUS triggers age-dependent synaptic impairment in presymptomatic ALS-FUS mice (RNA-seq part2) |
1.4 | | Slc1a6 | '9 day' vs '3 day' | time | Transcription profiling time series of mouse embryonic chondrocyte differentiation |
-1.4 | | Slc1a6 | 'Ink4a/Arf-/-; EGFRvIII' vs 'wild type genotype' in 'separate' | genotype, growth condition | RNA-seq of wild-type and transformed Ink4a/Arf-/-; EGFRvIII neural stem cells in separate or co-culture conditions |
1.4 | | Slc1a6 | 'West Nile virus; early stage encephalitis' vs 'mock infection' | infect, time | Transcriptomic profiling of the brains of WNV and CHIKV infection-induced encephalitis in young mice after 2, 3 or 5 days post infection |
-1.3 | | Slc1a6 | 'etoposide; 2.5 micromolar' vs 'none' in 'wild type genotype' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
-1.3 | | Slc1a6 | 'etoposide; 2.5 micromolar' vs 'none' in 'H2afj-∆7-KO' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
1.3 | | Slc1a6 | 'RAM siRNA' vs 'control' in 'polysomal RNA' | RNA interference, protocol | Transcription profiling by high throughput sequencing of mouse 46C embryonic stem cells transfected with RAM siRNA or control |
-1.3 | | Slc1a6 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'reticulocyte' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
-1.2 | | Slc1a6 | 'ductus arteriosis' vs 'aorta' | organism part | Gene Profiling in Mouse Fetal Ductus Arteriosus |
1.2 | | Slc1a6 | 'neurosphere in differentiation medium; 1 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
1.1 | | Slc1a6 | '8.5 millimolar; methoxyacetic acid' vs 'none' at '24 hour' | compound, time | Transcription profiling by array of mouse embryonic stem cells after treatment with 5-fluourouracil, methoxyacetic acid, monobutl phthalate, Penicillin G, retinoic acid or valproic acid |
1.1 | | Slc1a6 | '3 day; myogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn0' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-1.1 | | Slc1a6 | 'seizure-preconditioning followed by intra-amygdala kainic acid' vs 'sham-preconditioning followed by intra-amygdala vehicle' | clinical treatment | Transcription profiling by array of mice with epileptic tolerance |
-1.1 | | Slc1a6 | 'total RNA; HRasV12 and c-Myc overexpression and Eif4e wild type' vs 'total RNA; wild type' | fraction, genotype | Redefining the role of eIF4E dose in development, cancer, and protein synthesis |
1.1 | | Slc1a6 | 'proliferating progenitor' vs 'differentiating progenitor' | cell type | Transcription profiling by high throughput sequencing of proliferating neural stem cells, differentiating neurogenic progenitors and newborn neurons using a dual-reporter mouse line |
-1.1 | | Slc1a6 | '17beta-estradiol' vs 'DMSO' in 'wild type' | compound, genotype | Transcription profiling of mouse male embryos treated with DMSO or 17beta-estradiol in wild type or ERalpha knock outs to assess the toxic effects of oestrogen exposure in fetal testis |
1.1 | | Slc1a6 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'AKR/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
1 | | Slc1a6 | 'shRNA p68/p72 knockdown; growing' vs 'control; growing' on 'Affymetrix Array MOE430A' | RNA interference, developmental stage | Transcription profiling of p68/72 deficient C2C12 cells to investigate the function of p68/p72 in muscle gene expression and skeletal C2C12 cell differentiation. |
-1 | | Slc1a6 | 'Men1-null' vs 'wild type' | genotype | Differentially regulated genes in adipocytes derived from Men1-null vs WT mouse embryonic stem cells |
1 | | Slc1a6 | 'Id3 knockout' vs 'wild type' in 'Tet+CD24-CD44+NK1.1- Invariant natural killer T' | cell type, genotype | Essential functions for ID proteins at multiple checkpoints in natural killer T cell development |
1 | | Slc1a6 | 'mock inoculated' at '150 day' vs 'none' at '0 day' | infect, time | Transcription profiling by array of brains from mice infected with scrapie ME7 |
1 | | Slc1a6 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'C57BL/6J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
